Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
GLYC's Cash to Debt is ranked higher than
81% of the 1493 Companies
in the Global Biotechnology industry.

( Industry Median: 48.04 vs. GLYC: No Debt )
GLYC' s 10-Year Cash to Debt Range
Min: N/A   Max: No Debt
Current: No Debt


Warning: Division by zero in /home/gurufocu/public_html/include/common_stock_functions_2.php on line 6421
N/A
No Debt
Interest Coverage No Debt
GLYC's Interest Coverage is ranked higher than
69% of the 680 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. GLYC: No Debt )
GLYC' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

Z-Score: 22.22
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -87.48
GLYC's Operating margin (%) is ranked higher than
72% of the 1195 Companies
in the Global Biotechnology industry.

( Industry Median: -79.37 vs. GLYC: -87.48 )
GLYC' s 10-Year Operating margin (%) Range
Min: -265.19   Max: 24
Current: -87.48

-265.19
24
Net-margin (%) -87.37
GLYC's Net-margin (%) is ranked higher than
71% of the 1195 Companies
in the Global Biotechnology industry.

( Industry Median: -72.15 vs. GLYC: -87.37 )
GLYC' s 10-Year Net-margin (%) Range
Min: -265.61   Max: 23.96
Current: -87.37

-265.61
23.96
ROE (%) -24.12
GLYC's ROE (%) is ranked higher than
74% of the 1371 Companies
in the Global Biotechnology industry.

( Industry Median: -28.22 vs. GLYC: -24.12 )
GLYC' s 10-Year ROE (%) Range
Min: -137.43   Max: 34.84
Current: -24.12

-137.43
34.84
ROA (%) -22.35
GLYC's ROA (%) is ranked higher than
73% of the 1497 Companies
in the Global Biotechnology industry.

( Industry Median: -22.65 vs. GLYC: -22.35 )
GLYC' s 10-Year ROA (%) Range
Min: -89.49   Max: 15.45
Current: -22.35

-89.49
15.45
ROC (Joel Greenblatt) (%) -3051.53
GLYC's ROC (Joel Greenblatt) (%) is ranked higher than
58% of the 1457 Companies
in the Global Biotechnology industry.

( Industry Median: -358.68 vs. GLYC: -3051.53 )
GLYC' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1944.15   Max: 1623.95
Current: -3051.53

-1944.15
1623.95
» GLYC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

GLYC Guru Trades in Q1 2014

Steven Cohen 28,648 sh (New)
» More
Q2 2014

GLYC Guru Trades in Q2 2014

George Soros 10,300 sh (New)
» More
Q3 2014

GLYC Guru Trades in Q3 2014

George Soros Sold Out
» More
Q1 2015

GLYC Guru Trades in Q1 2015

Jim Simons 42,300 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with GLYC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 86.21
GLYC's Forward P/E is ranked higher than
87% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. GLYC: 86.21 )
N/A
P/B 3.70
GLYC's P/B is ranked higher than
77% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 6.60 vs. GLYC: 3.70 )
GLYC' s 10-Year P/B Range
Min: 1.81   Max: 5.35
Current: 3.7

1.81
5.35
P/S 11.70
GLYC's P/S is ranked higher than
76% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 40.71 vs. GLYC: 11.70 )
GLYC' s 10-Year P/S Range
Min: 7.37   Max: 105.13
Current: 11.7

7.37
105.13
EV-to-EBIT -9.00
GLYC's EV-to-EBIT is ranked higher than
86% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. GLYC: -9.00 )
GLYC' s 10-Year EV-to-EBIT Range
Min: -26.1   Max: -3.4
Current: -9

-26.1
-3.4
Current Ratio 11.54
GLYC's Current Ratio is ranked higher than
89% of the 1464 Companies
in the Global Biotechnology industry.

( Industry Median: 4.49 vs. GLYC: 11.54 )
GLYC' s 10-Year Current Ratio Range
Min: 2.14   Max: 21.83
Current: 11.54

2.14
21.83
Quick Ratio 11.54
GLYC's Quick Ratio is ranked higher than
89% of the 1464 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. GLYC: 11.54 )
GLYC' s 10-Year Quick Ratio Range
Min: 2.14   Max: 21.83
Current: 11.54

2.14
21.83
Days Sales Outstanding 0.02
GLYC's Days Sales Outstanding is ranked higher than
100% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 141.98 vs. GLYC: 0.02 )
GLYC' s 10-Year Days Sales Outstanding Range
Min: 0   Max: 0
Current: 0.02

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.90
GLYC's Price/Net Cash is ranked higher than
95% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 440.10 vs. GLYC: 3.90 )
GLYC' s 10-Year Price/Net Cash Range
Min: 2.31   Max: 5.65
Current: 3.9

2.31
5.65
Price/Net Current Asset Value 3.90
GLYC's Price/Net Current Asset Value is ranked higher than
95% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 48.94 vs. GLYC: 3.90 )
GLYC' s 10-Year Price/Net Current Asset Value Range
Min: 2.29   Max: 5.57
Current: 3.9

2.29
5.57
Price/Tangible Book 3.70
GLYC's Price/Tangible Book is ranked higher than
88% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 10.70 vs. GLYC: 3.70 )
GLYC' s 10-Year Price/Tangible Book Range
Min: 2.28   Max: 5.54
Current: 3.7

2.28
5.54
Price/Median PS Value 1.10
GLYC's Price/Median PS Value is ranked higher than
89% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. GLYC: 1.10 )
GLYC' s 10-Year Price/Median PS Value Range
Min: 0.8   Max: 9.9
Current: 1.1

0.8
9.9
Earnings Yield (Greenblatt) -11.10
GLYC's Earnings Yield (Greenblatt) is ranked higher than
59% of the 1456 Companies
in the Global Biotechnology industry.

( Industry Median: -5.50 vs. GLYC: -11.10 )
GLYC' s 10-Year Earnings Yield (Greenblatt) Range
Min: -12.1   Max: 0
Current: -11.1

-12.1
0

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:GKO.Germany,
» More Articles for GLYC

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
GlycoMimetics Initiates Phase 1/2 Clinical Trial of GMI-1271 as Potential Treatment for Acute... May 19 2015
GlycoMimetics Initiates Phase 1/2 Clinical Trial of GMI-1271 as Potential Treatment for Acute... May 19 2015
GlycoMimetics' Leukemia Drug Gets Orphan Status in U.S. - Analyst Blog May 15 2015
FDA Grants Orphan Drug Designation To GlycoMimetics' GMI-1271 For Treatment of Acute Myleogenous... May 14 2015
FDA Grants Orphan Drug Designation To GlycoMimetics’ GMI-1271 For Treatment of Acute Myleogenous... May 14 2015
GLYCOMIMETICS INC Financials May 13 2015
GlycoMimetics reports 1Q loss May 05 2015
GlycoMimetics Reports First Quarter 2015 Results May 05 2015
GLYCOMIMETICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... May 05 2015
GlycoMimetics Reports First Quarter 2015 Results May 05 2015
Nasdaq stocks posting largest percentage increases Apr 29 2015
GLYCOMIMETICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Apr 07 2015
GlycoMimetics Provides Update on Pfizer's Plans to Initiate Phase 3 Trial with Rivipansel in... Apr 07 2015
GlycoMimetics Provides Update on Pfizer’s Plans to Initiate Phase 3 Trial with Rivipansel in... Apr 07 2015
GlycoMimetics to Present First Preclinical Data on E-selectin-CXCR4 Dual Antagonist for Cancer... Mar 20 2015
GlycoMimetics to Present First Preclinical Data on E-selectin-CXCR4 Dual Antagonist for Cancer... Mar 19 2015
GLYCOMIMETICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Mar 16 2015
GlycoMimetics Reports Fourth Quarter and Year-End 2014 Results Mar 16 2015
GLYCOMIMETICS INC Files SEC form 10-K, Annual Report Mar 16 2015
GlycoMimetics Reports Fourth Quarter and Year-End 2014 Results Mar 16 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK